Skip to main content

Mutz Christopher's Form 4 filing

Ani Pharmaceuticals IncANIP · filed Feb 17, 2026

Accession no.
0001846487-26-000004
Filed
Feb 17, 2026
Trade date
Feb 12-14, 2026
Filing delay
5 days
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions. Open-market sales total $538.3K. It was filed 5 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Mutz ChristopherCIK 0001846487Officer (HEAD OF RARE DISEASE)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 12, 2026Common StockFTax withholdingDisposed−3,173$76.70−$243,369.199,598Direct
Feb 12, 2026Common StockSSaleDisposed−7,032$76.55F3−$538,299.692,566Direct
Feb 14, 2026Common StockFTax withholdingDisposed−2,403$77.36−$185,896.0890,163Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F3

The shares were sold in multiple trades at prices ranging from $75.43 to $76.92. The price reported above reflects the weighted average sales price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)